The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Multidisciplinary approach in treating immunotherapy-resistant GI cancers
Xuefeng Leng, MD, PhD, University of Electronic Science and Technology of China (UESTC), Chengdu, China, discusses the ongoing challenges in oncology, particularly in treating patients with cancers such as esophageal squamous cell carcinoma, where immunotherapy may not be effective for all patients. Given the complexity of these cases, Dr Leng urges for cancer centers to organize multidisciplinary team (MDT) discussions that go beyond clinical data. Pathological data plays a crucial role in making informed decisions, and by leveraging the expertise of a diverse team, therapies can be tailored to meet the specific needs of each patient. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
